Six Novel Pseudomonas aeruginosa Phages: Genomic Insights and Therapeutic Potential
PHAGE,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 21, 2025
Introduction:
Pseudomonas
aeruginosa
is
an
opportunistic
pathogen
that
causes
health
care-associated
infections.
The
rise
of
antibiotic-resistant
bacterial
strains
necessitates
alternative
treatment
strategies,
with
bacteriophage
therapy
being
a
promising
approach.
Language: Английский
Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections
Infectious Disease Reports,
Journal Year:
2024,
Volume and Issue:
16(6), P. 1127 - 1181
Published: Nov. 28, 2024
Background:
Phage
therapy,
a
treatment
utilizing
bacteriophages
to
combat
bacterial
infections,
is
gaining
attention
as
promising
alternative
antibiotics,
particularly
for
managing
antibiotic-resistant
bacteria.
This
study
aims
provide
comprehensive
review
of
phage
therapy
by
examining
its
safety,
efficacy,
influencing
factors,
future
prospects,
and
regulatory
considerations.
The
also
seeks
identify
strategies
optimizing
application
propose
systematic
framework
clinical
implementation.
Methods:
A
analysis
preclinical
studies,
trials,
frameworks
was
undertaken
evaluate
the
therapeutic
potential
therapy.
included
an
in-depth
assessment
key
factors
outcomes,
such
infection
site,
phage–host
specificity,
burden,
immune
response.
Additionally,
innovative
strategies—such
combination
therapies,
bioengineered
phages,
cocktails—were
explored
enhance
efficacy.
Critical
considerations
related
dosing,
including
inoculum
size,
multiplicity
infection,
windows,
personalized
medicine
approaches,
were
examined
optimize
outcomes.
Results:
has
demonstrated
favorable
safety
profile
in
both
settings,
with
minimal
adverse
effects.
Its
ability
specifically
target
harmful
bacteria
while
preserving
beneficial
microbiota
underpins
efficacy
treating
range
infections.
However,
variable
outcomes
some
studies
highlight
importance
addressing
critical
that
influence
success.
Innovative
expanded
access
diverse
banks,
cocktails,
medicine,
hold
significant
promise
improving
Optimizing
dosing
remains
area
enhancement,
kinetics,
resistance
potential,
frequency,
patient-specific
factors.
To
support
streamlined
four-step
guideline
been
developed,
providing
effective
planning
Conclusion:
offers
highly
adaptable,
targeted,
cost-effective
approach
While
several
must
be
thoroughly
evaluated
there
improvement
through
refined
methodologies.
Although
yet
achieve
widespread
approval
U.S.
Europe,
accessibility
Expanded
Access
programs
FDA
authorizations
food
pathogen
control
underscores
promise.
Established
practices
countries
Poland
Georgia
further
demonstrate
feasibility.
enable
broader
adoption,
harmonization
advancements
production,
delivery,
quality
will
essential.
Notably,
affordability
scalability
position
it
especially
valuable
solution
developing
regions
grappling
escalating
rates
antibiotic
resistance.
Language: Английский
PaAP-Activatable NIR Probe for Diagnosing, Imaging, and Discovering Small-Molecule Therapeutics against Implant-Associated Biofilm Infections
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 26, 2025
Biofilm
formation
on
medical
implants
causes
implant-associated
infections
(IAIs),
leading
to
high
morbidity
and
mortality.
Developing
molecular
tools
for
precise
biofilm
detection,
along
with
novel
strategies
agents
target
biofilm-related
IAIs,
is
crucial
improving
treatment
options
patient
outcomes.
Pseudomonas
aeruginosa
aminopeptidase
(PaAP),
a
key
biofilm-associated
virulence
factor,
promising
combating
infections.
Here,
we
developed
PaAP-activatable
near-infrared
(NIR)
fluorescent
probe,
Hcy-NEO-Leu,
real-time,
specific,
sensitive
detection
of
PaAP
activity.
This
probe
enables
noninvasive
imaging
the
P.
in
vitro
vivo.
The
also
identified
LY-58,
lycorine
derivative
that
disrupts
without
affecting
bacterial
growth
or
mammalian
cell
viability,
enhancing
tobramycin
penetration
overcoming
antibiotic
resistance.
study
introduces
LY-58
as
adjunctive
therapy.
In
conclusion,
NIR
combined
offers
innovative
early
diagnosis
effective
IAIs.
Language: Английский
A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections
PHAGE,
Journal Year:
2024,
Volume and Issue:
5(4), P. 203 - 222
Published: Oct. 17, 2024
Rising
antibiotic
resistance
among
bacterial
pathogens
has
become
a
substantial
health
issue
for
human
civilization.
The
emergence
of
these
in
high-risk
diseases
such
as
cystic
fibrosis
(CF)
led
to
financial
and
nonfinancial
losses,
necessitating
alternative
therapies.
This
study
presents
an
overview
approaches,
including
phage
therapy,
antimicrobial
peptides
(AMPs),
nanotechnology,
monoclonal
antibodies
(mAbs),
microbial
therapies
(probiotic
therapy),
clustered
regularly
interspaced
short
palindromic
repeats
technology
(CRISPR),
aptamers
focusing
on
their
mechanisms
action
exploring
the
impact
combining
derivatives
with
mentioned
approaches.
Although
approaches
combinations
phages
show
promise,
phage-antibiotic
combination
been
subject
most
studies,
It
proven
be
highly
effective
combating
antibiotic-resistant
infections.
Other
also
appear
promising,
but
further
studies
are
needed
determine
effectiveness.
emphasizes
need
more
thorough
research
into
different
treatments
beyond
well-established
strategy.
Language: Английский
Challenges and opportunities of phage therapy for Klebsiella pneumoniae infections
Xin Kou,
No information about this author
Xiaoyu Yang,
No information about this author
Rui Zheng
No information about this author
et al.
Applied and Environmental Microbiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 30, 2024
ABSTRACT
Traditional
antibiotics
have
been
effective
in
many
cases.
However,
the
rise
multidrug-resistant
bacteria
has
diminished
their
therapeutic
efficacy,
signaling
dawn
of
an
era
beyond
antibiotics.
The
challenge
multidrug
resistance
Klebsiella
pneumoniae
is
particularly
critical,
with
increasing
global
mortality
and
rates.
Therefore,
development
alternative
therapies
to
urgently
needed.
Phages,
which
are
natural
predators
bacteria,
inherent
advantages.
comprehensive
information
on
K.
phages
lacking
current
literature.
This
review
aims
analyze
summarize
relevant
studies,
focusing
present
state
phage
therapy
for
infections.
includes
examination
treatment
methodologies,
associated
challenges,
strategies,
new
technologies,
clinical
trial
safety
regulatory
issues,
future
directions
development.
Enhancing
technology
crucial
addressing
evolving
threat
.
Language: Английский
Phage diversity in One Health
Essays in Biochemistry,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 30, 2024
Abstract
One
Health
aims
to
bring
together
human,
animal,
and
environmental
research
achieve
optimal
health
for
all.
Bacteriophages
(phages)
are
viruses
that
kill
bacteria
their
utilisation
as
biocontrol
agents
in
the
environment
therapeutics
animal
human
medicine
will
aid
achievement
of
objectives.
Here,
we
assess
diversity
phages
used
last
5
years
place
them
context
global
phage
diversity.
Our
review
shows
98%
applied
belong
class
Caudoviricetes,
compared
85%
sequenced
belonging
this
class.
Only
three
RNA
from
realm
Riboviria
have
been
therapy
date.
This
emphasises
lack
commercially
therapy,
which
may
be
due
biases
methods
both
isolate
select
applications.
The
future
depend
on
ability
genetically
novel
dsDNA
phages,
well
improving
efforts
ssDNA
potential
is
currently
undervalued.
Phages
reduce
burden
antimicrobial
resistance,
however,
underutilising
vast
present
nature.
More
into
genomics
alternative
culture
required
fully
understand
complex
relationships
between
hosts,
other
organisms
Language: Английский